Aged garlic extract improves adiponectin levels in subjects with metabolic syndrome: A double-blind, placebo-controlled, randomized, crossover study

Diego Gómez-Arbeláez, Vicente Lahera, Pilar Oubiña, Maria Valero-Muñoz, Natalia De Las Heras, Yudy Rodríguez, Ronald Gerardo García, Paul Anthony Camacho, Patricio López-Jaramillo

Research output: Contribution to journalArticlepeer-review

43 Scopus citations

Abstract

Background. Garlic (Allium sativum) has been shown to have important benefits in individuals at high cardiovascular risk. The aim of the present study was to evaluate the effects of the administration of aged garlic extract (AGE) on the risk factors that constitute the cluster of metabolic syndrome (MS). Methods and Design. Double-blind, crossover, randomized, placebo-controlled clinical trial to assess the effect of 1.2 g/day of AGE (Kyolic), for 24 weeks of treatment (12 weeks of AGE and 12 weeks of placebo), on subjects with MS. Results. The administration of AGE increased the plasma levels of adiponectin (P=0.027). No serious side effects associated with the intervention were reported. Conclusion. The present results have shown for the first time that the administration of AGE for 12 weeks increased plasma adiponectin levels in patients with MS. This suggests that AGE might be a useful, novel, nonpharmacological therapeutic intervention to increase adiponectin and to prevent cardiovascular (CV) complications in individuals with MS.

Original languageEnglish
Article number285795
JournalMediators of Inflammation
Volume2013
DOIs
StatePublished - 2013
Externally publishedYes

Fingerprint

Dive into the research topics of 'Aged garlic extract improves adiponectin levels in subjects with metabolic syndrome: A double-blind, placebo-controlled, randomized, crossover study'. Together they form a unique fingerprint.

Cite this